170 related articles for article (PubMed ID: 25078132)
1. Pharmaceutical R&D: an age of change?
Baldwin JJ
Future Med Chem; 2014 Jun; 6(10):1109-12. PubMed ID: 25078132
[No Abstract] [Full Text] [Related]
2. Drug Regulation and Pricing--Can Regulators Influence Affordability?
Eichler HG; Hurts H; Broich K; Rasi G
N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
[No Abstract] [Full Text] [Related]
3. Skies darken over drug companies.
Holmes D
Lancet; 2012 May; 379(9829):1863-4. PubMed ID: 22616103
[No Abstract] [Full Text] [Related]
4. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
5. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
6. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
[TBL] [Abstract][Full Text] [Related]
7. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
Ablavsky G; Larrimore Ouellette L
JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
[No Abstract] [Full Text] [Related]
8. Inadequately met needs.
Nat Biotechnol; 2011 May; 29(5):371. PubMed ID: 21552219
[No Abstract] [Full Text] [Related]
9. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
10. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
11. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M; Wu J
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
[TBL] [Abstract][Full Text] [Related]
12. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
13. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
Sklan A
Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
[No Abstract] [Full Text] [Related]
14. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
15. Handle with care.
Macilwain C
Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
[No Abstract] [Full Text] [Related]
16. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
17. [Free trade agreements make the drugs more expensive].
Jeppsson A
Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
[No Abstract] [Full Text] [Related]
18. Protect pharmaceutical innovation.
Musselwhite LW; Andrews J
Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
[No Abstract] [Full Text] [Related]
19. Are we living in the end of the blockbuster drug era?
Debnath B; Al-Mawsawi LQ; Neamati N
Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
[TBL] [Abstract][Full Text] [Related]
20. Strategic options for brand-name prescription drugs when patents expire.
Mehta SC; Mehta SS
Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
